--- title: "Recurrence detection with current surveillance in operable triple-negative breast cancer: a micros" id: "bmj-open-1-recurrence-detection-in-patients-with-triple-negative-breast-cancer-following" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-1-recurrence-detection-in-patients-with-triple-negative-breast-cancer-following" content_type: "clinical_feed_article" specialty: "Oncology" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/9/e115240?rss=1" published_at: "2026-09-16T13:30:50.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Recurrence detection with current surveillance in operable triple-negative breast cancer: a micros ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-1-recurrence-detection-in-patients-with-triple-negative-breast-cancer-following - **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/9/e115240?rss=1) - **Published At:** 2026-09-16T13:30:50.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - The study used an individual-level state-transition **microsimulation** model to evaluate recurrence detection under current surveillance recommendations for operable stage II and III **triple-negative breast cancer (TNBC)**. - The model simulated monthly cycles over a lifetime horizon for a cohort of female patients aged 49 years newly diagnosed with operable stage II or III TNBC, integrating treatment and surveillance per current guidelines. - Primary outcomes within a 5-year horizon included cumulative recurrences, detected recurrences, detection rate, overall survival (OS), recurrence-free survival (RFS), and average life expectancy. - The model estimated a 5-year OS of **81.4% ± 0.1% (SE)** and a 5-year RFS of **78.3% ± 0.1% (SE)** for the cohort. - It projected that **7.4% ± 0.1% (SE)** of patients would experience recurrence within 5 years, with **68%** of recurrences distant and **32%** locoregional. - The modeled detection rate of those recurrences under current guideline-based surveillance was **59.3% ± 0.2% (SE)**, indicating many recurrences went undetected by standard follow-up. - Resource-efficiency findings included an estimate that **399 mammograms** would be required to detect one locoregional recurrence and **279 other imaging tests** would be needed to detect one distant recurrence. - The authors conclude that guideline-concordant surveillance has limitations in recurrence detection for TNBC and that the validated model can be used to assess how novel testing methods may alter surveillance effectiveness and patient outcomes. ## Clinical Analysis & Structured Key Points Objectives Breast cancer is the most common cancer among women in the USA, accounting for approximately 31% of new cases and 15% of cancer-related deaths in females. Triple-negative breast cancer (TNBC) is the most lethal subtype with 29 months median overall survival. Despite curative-intent surgery and systemic adjuvant therapy, many patients remain at risk for recurrence. We developed a comprehensive model for patients with operable stage II and III TNBC, adhering to the current standard-of-care clinical follow-up recommendations, to evaluate the effectiveness of these recommendations in detecting recurrence among patients with newly diagnosed TNBC. Design An individual-level state transition (microsimulation) model was built with a lifetime horizon using monthly cycles. The model integrated treatment and surveillance recommendations per current guidelines. Setting The currently recommended treatment and surveillance modalities by the National Comprehensive Cancer Network guidelines for surveilling patients with TNBC after diagnosis. Participants Female patients aged 49 years who were newly diagnosed with operable stage II or III TNBC. Outcome measures Cumulative recurrences, detected recurrences, detection rate, overall survival and recurrence-free survival in a 5-year horizon, as well as average life expectancy, were the outcome measures used. Results Our model estimated a 5-year overall survival rate of 81.4%±0.1% (SE) for patients with stage II or III TNBC, with a recurrence-free survival rate of 78.3%±0.1% (SE). Over the same period, 7.4%±0.1% (SE) of patients with TNBC were projected to experience recurrences (68% distant recurrence, 32% locoregional recurrence), with a detection rate of only 59.3%±0.2% (SE) among these recurrences. Our model estimated that 399 mammograms would be required to detect one locoregional recurrence and 279 other imaging tests would be needed to identify one distant recurrence. Conclusions Our clinically validated model sheds light on the outcomes for patients with TNBC, revealing the limitations in recurrence detection rates associated with current guidelines. These findings underscore the need for improved strategies during the surveillance period. As novel testing methods become available, this model can be instrumental in exploring how these innovations may improve patient outcomes. ## Related Clinical Research - [Investigation finds 20 unnecessary mastectomies at County Durham and Darlington trust](https://medichelpline.com/clinical-feed/bmj-2-mastectomy-scandal-twenty-women-had-unnecessary-procedure-at-trust.md) - [Inflammatory Biomarkers and Risk of Postmenopausal ER-Positive Breast Cancer](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-receptor-positive.md) - [ChatGPT versus Gemini for Patient-Facing Breast Cancer Questions: Comparative Evaluation](https://medichelpline.com/clinical-feed/plos-one-13-comparative-evaluation-of-chatgpt-and-gemini-responses-to-patient-oriented.md) - [Pemetrexed Stabilizes BRCA1 and Enhances Radiosensitivity in Triple‑Negative Breast Cancer](https://medichelpline.com/clinical-feed/pubmed-42757486.md) (DOI: 10.3892/or.2026.9194) - [Pretrained gene representations transfer mean expression more than spatial patterns in virtual spa](https://medichelpline.com/clinical-feed/biorxiv-10-pretrained-gene-representations-transfer-mean-expression-more-broadly-than.md) ## Navigation - [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.